Intracellularly, TH1L has been reported to act as a negative regulator of A‐Raf and PAK1, suppressing the MEK/ERK signalling pathway to regulate cancer progression through its impacts on cellular migration, invasion and epithelial‐mesenchymal transition (EMT).9, 10. The gene discussed is NELFCD; the disease is cancer.